Management of Cardiac Complications in Kawasaki Disease
Children with coronary artery aneurysms from Kawasaki disease require risk-stratified antithrombotic therapy: low-dose aspirin (3-5 mg/kg/day) alone for small aneurysms, and combination anticoagulation plus antiplatelet therapy for giant aneurysms (Z-score >10 or absolute diameter ≥8mm). 1
Acute Phase Treatment to Prevent Aneurysms
The primary goal is preventing coronary complications through early intervention:
- IVIG 2 g/kg as a single infusion (over 10-12 hours) plus aspirin within the first 10 days of illness 1, 2
- High-dose aspirin during acute phase: 80-100 mg/kg/day divided every 6 hours (US dosing) 1
- Continue high-dose aspirin until afebrile for 48-72 hours, then transition to low-dose 1
Despite optimal treatment, 20% develop transient coronary dilation, 5% develop aneurysms (Z-score >2.5), and 1% develop giant aneurysms 1. This underscores that even with guideline-adherent therapy, cardiac complications remain a significant risk.
Long-Term Antithrombotic Management Based on Aneurysm Severity
No Coronary Abnormalities at 6-8 Weeks
- Low-dose aspirin (3-5 mg/kg/day) until 6-8 weeks post-onset, then discontinue if echocardiography remains normal 1
Small to Moderate Aneurysms
- Low-dose aspirin indefinitely as monotherapy 1, 3
- Critical caveat: Avoid ibuprofen as it antagonizes aspirin's irreversible platelet inhibition 1
Giant Aneurysms
- Aspirin PLUS warfarin for dual antithrombotic coverage 3
- This combination addresses both platelet aggregation and coagulation cascade activation in high-risk vessels
Surveillance for Late Complications
Even regressed aneurysms carry long-term risk:
- Localized stenosis with coronary calcification can develop >10 years after KD onset 4
- Aneurysms with initial maximum diameter >5.0 mm (Z-score >6.7) have highest risk for calcification 4
- Standard ECG and exercise testing may miss significant stenosis—multimodal imaging including CT angiography is essential for adequate surveillance 5
The 25-year cardiac event-free survival for regressed aneurysms is 95.3%, but all cases of localized stenosis were associated with coronary calcification 4, emphasizing the need for lifelong monitoring in patients with any history of coronary involvement.
Interventional and Surgical Options
For patients developing ischemic complications:
- Acute coronary thrombosis: Platelet IIb/IIIa antagonists and thrombolytic therapy 3
- Chronic stenosis with ischemia: Coronary artery bypass grafting using internal thoracic artery (ITA) grafts, which demonstrate excellent long-term patency and growth potential in pediatric patients 6
- Transcatheter interventions (angioplasty) for appropriate lesions 3, 5
The ITA has become the preferred conduit for pediatric coronary bypass due to superior long-term outcomes and growth capacity 6.
Key Clinical Pitfalls
- Reye syndrome risk: Children on aspirin therapy who develop varicella or influenza require immediate aspirin discontinuation 1
- Delayed diagnosis of stenosis: Routine non-invasive testing may be falsely reassuring—maintain high suspicion and use advanced imaging 5
- Medication interactions: NSAIDs like ibuprofen must be avoided in patients on antiplatelet aspirin 1
- Vaccine timing: Defer measles, mumps, and varicella immunizations for 11 months post-IVIG 1
The management algorithm hinges on accurate coronary artery assessment and risk stratification, with therapy intensity escalating proportionally to aneurysm size and thrombotic risk.